Vaxart, Inc.
NASDAQ:VXRTBiotechnology
-$0.01 today
- Market cap
- $129.30M
- Beta
- 1.09
- P/E (TTM)
- 3.6
- EPS (TTM)
- $0.15
Volume 0.12M
Average 0.41M
VXRT Total Non-current Assets
All assets not expected to be converted to cash within one year.
Vaxart, Inc.NASDAQ: VXRT
Total Non-current Assets · Q1 FY2026 · quarter ended Mar 2026
Total non-current assets falls 49.6% from a year ago
Total non-current assets stood at $48.35M at the end of Q1 FY2026, down 49.6% from a year earlier and down 3.2% from the prior quarter. Over 3 fiscal years it compounded at -2.8% a year.
Context
- Total non-current assets amounted to 26.9% of total assets at the end of Q1 FY2026, down 33.6 pp from a year earlier.
- Total non-current assets increased in 1 of the last 3 fiscal years.
What to watch
Whether total non-current assets keeps falling in the next quarterly balance sheet after a -49.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Non-current Assets history
USD · from the balance sheet
- Latest · FY2025
- 49.96M USD
- Year-over-year change
- -49.1%
- 4-year CAGR
- -1.0%
| Period | Period end | Total Non-current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 49.96M | -49.1% |
| FY2024 | 2024-12-31 | 98.13M | +112.0% |
| FY2023 | 2023-12-31 | 46.29M | -14.9% |
| FY2022 | 2022-12-31 | 54.4M | +4.6% |
| FY2021 | 2021-12-31 | 52M | — |
Total Non-current Assets vs competitors
How VXRT compares with its peers on the latest reported figures
- VXRT's Mar 2026 total non-current assets of $48.35M is the 4th highest of the 10 companies compared; the peer median is $3.26M.
- Its year-over-year change of -49.6% is the 7th highest of 10, against a peer median of -11.3%.
- Total non-current assets amounts to 26.9% of total assets for VXRT, versus a peer median of 3.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
CBUSCibus, Inc. | Mar 2026 | $291.13M | -5.8% | +152.1% | 89.8% |
| Mar 2026 | $69.23M | -11.1% | -1.5% | 34.3% | |
| Mar 2026 | $61.39M | +20.0% | -1.1% | 17.2% | |
| Mar 2026 | $48.35M | -49.6% | -2.8% | 26.9% | |
ACRVAcrivon Therapeutics, Inc. Common Stock | Mar 2026 | $8.61M | -65.6% | -42.6% | 8.0% |
| Mar 2026 | $3.26M | -70.6% | — | 3.1% | |
| Mar 2026 | $983K | -36.2% | -14.4% | 0.5% | |
| Mar 2026 | $861K | +43.3% | +0.0% | 1.3% | |
| Mar 2026 | $782K | -89.0% | -61.4% | 0.8% | |
| Mar 2026 | $19.5K | -11.3% | -17.6% | 0.0% | |
| Peer median (excluding VXRT) | $3.26M | -11.3% | -8.0% | 3.1% | |
Competitors are the stored peer set for VXRT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 143.75M | 44.01M | 34.76M | 25.23M | 53.81M |
| Short-term Investments | 22.74M | 49.7M | 4.96M | 26.49M | 9.99M |
| Net Receivables | 71K | 20K | 3.01M | 11.97M | 51.35M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 2M | 333K | 318K | 667K |
| Total Current Assets | 169.17M | 99.45M | 45.54M | 68.26M | 136.12M |
| Property, Plant & Equipment (Net) | 19.77M | 41.3M | 36.57M | 29.11M | 16.87M |
| Goodwill | 4.51M | 4.51M | 4.51M | 4.51M | 4.51M |
| Intangible Assets | 10.62M | 5.02M | 4.29M | 3.56M | 2.83M |
| Long-term Investments | 16.21M | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 890K | 3.57M | 926K | 60.96M | 25.76M |
| Total Non-current Assets | 52M | 54.4M | 46.29M | 98.13M | 49.96M |
| Total Assets | 221.17M | 153.85M | 91.83M | 166.39M | 186.08M |
| Account Payables | 3.87M | 5.51M | 1.58M | 6.96M | 21.5M |
| Short-term Debt | 836K | 95K | 3.8M | 4.06M | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 13.02M |
| Other Current Liabilities | 1 | 2M | 0 | 65.4M | 5.63M |
| Total Current Liabilities | 10.78M | 17.92M | 13.72M | 90.88M | 86.75M |
| Long-term Debt | 10.69M | 5.62M | 2.62M | 1.7M | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 2.02M |
| Other Non-current Liabilities | 171K | 231K | 293K | 439K | 3.5M |
| Total Non-current Liabilities | 22.85M | 25.33M | 20.3M | 16.59M | 11.53M |
| Total Liabilities | 33.64M | 43.25M | 34.03M | 107.46M | 98.28M |
| Common Stock | 13K | 13K | 15K | 23K | 24K |
| Retained Earnings | (219.35M) | (327.11M) | (409.57M) | (476.52M) | (460.2M) |
| Accumulated OCI | (74K) | (299K) | (1K) | 4K | (3K) |
| Other Stockholders Equity | (0) | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 187.53M | 110.6M | 57.81M | 58.93M | 87.8M |
| Total Debt | 24.53M | 27.42M | 26.51M | 23.28M | 8.99M |
| Net Debt | (119.22M) | (16.59M) | (8.24M) | (1.95M) | (44.83M) |
Vaxart, Inc.
NASDAQ:VXRT
Intrinsic Alpha fair value
Locked
Current Price
$0.53
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.